SCG Cell Therapy Pte Ltd (SCG), a clinical-stage biotechnology company pioneering TCR T cell therapy for infectious diseases and associated cancers, today announced late-breaking clinical data from ...

Berlin: Bayer has announced the initiation of a Phase I clinical trial with 225Ac-GPC3 (BAY 3547926), an investigational ...

in patients with advanced HBV-related hepatocellular carcinoma (HCC). These data were presented at the European Association for the Study of the Liver (EASL) Congress 2025. The results ...

General and Administrative (G&A) Expenses. G&A expenses for the three months ended March 31, 2025 were $6.9 million compared to $5.1 million for the same period in 2024. The increase was primarily ...

DelveInsight's Hepatocellular Carcinoma pipeline report depicts a robust space with 90+ active players working to develop 95+ pipeline therapies for Hepatocellular Carcinoma treatment.

Radiomics Group, led by Raquel Perez-Lopez, have developed SALSA (System for Automatic Liver tumor Segmentation And detection ...

In early-stage HCC patients (BCLC 0 and A), CP mRNA was elevated in 67.9% of cases, outperforming AFP, which detected only 46 ...

The risk of dying from the most common form of primary liver cancer is approximately 30% higher for patients with low ...

The risk of dying from the most common form of primary liver cancer is about 30% higher for patients with low household ...

A phase 3 trial shows that once-weekly semaglutide significantly improves liver histology in patients with metabolic ...

The risk of dying from the most common form of primary liver cancer is about 30 percent higher for patients with low household income compared to those with middle or high household income, according ...